These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 30157803)
1. Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours. Lawrence NJ; Chan H; Toner G; Stockler MR; Martin A; Yip S; Wong N; Yeung A; Mazhar D; Pashankar F; Frazier L; McDermott R; Walker R; Tan H; Davis ID; Grimison P; BMC Cancer; 2018 Aug; 18(1):854. PubMed ID: 30157803 [TBL] [Abstract][Full Text] [Related]
2. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604). Huddart RA; Gabe R; Cafferty FH; Pollock P; White JD; Shamash J; Cullen MH; Stenning SP; ; Eur Urol; 2015 Mar; 67(3):534-43. PubMed ID: 25001888 [TBL] [Abstract][Full Text] [Related]
3. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC; Ann Oncol; 2014 Jan; 25(1):143-8. PubMed ID: 24356625 [TBL] [Abstract][Full Text] [Related]
4. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363 [TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604). Cafferty FH; White JD; Shamash J; Hennig I; Stenning SP; Huddart RA; Eur J Cancer; 2020 Mar; 127():139-149. PubMed ID: 32007714 [TBL] [Abstract][Full Text] [Related]
6. Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour. Rimmer Y; Chester J; Joffe J; Stark D; Shamash J; Powles T; White J; Wason J; Parashar D; Armstrong G; Mazhar D; Williams MV Br J Cancer; 2011 Sep; 105(6):766-72. PubMed ID: 21847130 [TBL] [Abstract][Full Text] [Related]
7. Bleomycin, etoposide and cisplatinum (BEP) chemotherapy for metastatic germ cell tumours: treatment outcomes at UKM medical centre, Malaysia. Azrif M; Leong YK; Aslan NM; Fong KV; Ismail F Asian Pac J Cancer Prev; 2012; 13(6):2467-71. PubMed ID: 22938405 [TBL] [Abstract][Full Text] [Related]
8. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948). Fosså SD; Paluchowska B; Horwich A; Kaiser G; de Mulder PH; Koriakine O; van Oosterom AT; de Prijck L; Collette L; de Wit R; Br J Cancer; 2005 Nov; 93(11):1209-14. PubMed ID: 16251877 [TBL] [Abstract][Full Text] [Related]
9. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712 [TBL] [Abstract][Full Text] [Related]
10. A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3). Shamash J; Sarker SJ; Huddart R; Harland S; Joffe JK; Mazhar D; Birtle A; White J; Chowdhury K; Wilson P; Marshall MR; Vinnicombe S Ann Oncol; 2017 Jun; 28(6):1333-1338. PubMed ID: 28327896 [TBL] [Abstract][Full Text] [Related]
11. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP; J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419 [TBL] [Abstract][Full Text] [Related]
12. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours. Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R; Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368 [TBL] [Abstract][Full Text] [Related]
13. Treatment outcome and cost-effectiveness analysis of two chemotherapeutic regimens (BEP vs. VIP) for poor-prognosis metastatic germ cell tumors. Attili VS; Chandra RC; Anupama G; Loknath D; Bapsy PP; Dadhich HK; Babu GK J Cancer Res Ther; 2007; 3(3):150-2. PubMed ID: 18079577 [TBL] [Abstract][Full Text] [Related]
14. Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours. Anthoney DA; McKean MJ; Roberts JT; Hutcheon AW; Graham J; Jones W; Paul J; Kaye SB Br J Cancer; 2004 Feb; 90(3):601-6. PubMed ID: 14760371 [TBL] [Abstract][Full Text] [Related]
15. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042 [TBL] [Abstract][Full Text] [Related]
16. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study. Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427 [TBL] [Abstract][Full Text] [Related]
17. Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. Fizazi K; Le Teuff G; Fléchon A; Pagliaro L; Mardiak J; Geoffrois L; Laguerre B; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Cancel M; Juzyna B; Reckova M; Naoun N; Logothetis C; Culine S J Clin Oncol; 2024 Oct; 42(28):3270-3276. PubMed ID: 39167741 [No Abstract] [Full Text] [Related]
18. Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer. Kawai K; Akaza H Cancer Sci; 2010 Jan; 101(1):22-8. PubMed ID: 19922501 [TBL] [Abstract][Full Text] [Related]
19. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Daugaard G; Skoneczna I; Aass N; De Wit R; De Santis M; Dumez H; Marreaud S; Collette L; Lluch JRG; Bokemeyer C; Schmoll HJ Ann Oncol; 2011 May; 22(5):1054-1061. PubMed ID: 21059637 [TBL] [Abstract][Full Text] [Related]
20. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy. Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]